News & Insights

Risk Factor Modification Tools for Atrial Fibrillation Treatment

March 16, 2026
Doctor talking to patient

In atrial fibrillation (AF), common modifiable conditions contribute to atrial remodeling and create a substrate for recurrent arrhythmia. Recent literature and guideline-aligned care pathways increasingly emphasize lifestyle and comorbidity management alongside rate/rhythm control.¹ This article highlights key modifiable risk factors and practical tools—targeting obesity, hypertension, sleep apnea, physical inactivity, diabetes, alcohol use, and tobacco exposure—to improve outcomes in AF.

 

Obesity

  • Tools: Structured nutrition plan, calorie tracking, referral to weight-management/cardiac rehab, and use of anti-obesity pharmacotherapy when appropriate.1,2
  • Evidence: In patients with AF and obesity, a contemporary randomized trial (PRAGUE-25) demonstrated that catheter ablation achieved higher 1-year freedom from AF than lifestyle modification plus antiarrhythmic drugs, yet weight loss was more significant in the lifestyle intervention in combination with antiarrhythmic drugs—supporting doing both rather than delaying rhythm strategies.²

 

Hypertension

  • Tools: Home blood pressure (BP) monitoring with structured logs supported by clinical feedback and team-based care, along with dietary approaches such as reduced sodium intake and DASH-style eating patterns to lower BP.3,4
  • Evidence: Risk factor management reviews emphasize BP control as a foundational AF strategy, especially around ablation outcomes.5

 

Sleep Apnea

  • Tools: Screening (STOP-BANG questionnaire to identify individuals at high risk for obstructive sleep apnea), diagnostic testing, and continuous positive airway pressure (CPAP) setup with adherence monitoring.6,7
  • Evidence: Systematic reviews (PubMed/Scopus searched) suggest CPAP may reduce AF progression/recurrence, though higher-quality randomized controlled trials (RCTs) are still needed.8

 

Physical Activity

  • Tools: Structured aerobic exercise programs, often combined with resistance training, delivered through supervised cardiac rehabilitation or guided home-based programs, with activity tracking to support adherence.9,10
  • Evidence: Higher physical activity and cardiorespiratory fitness are consistently associated with better outcomes in AF cohorts.11

 

Diabetes and GLP-1–based therapies

  • Tools: Weight-centric glucose-lowering therapy using GLP-1 receptor agonists/co-agonists, with continuous glucose monitoring in appropriate patients to guide management.12,13
  • Evidence: A 2025 systematic review and meta-analysis of RCTs found GLP-1–based therapies were associated with a lower risk of incident AF in patients who were overweight or obese.14

 

Alcohol and tobacco

  • Tools: Modifying alcohol consumption and smoking status.15,16
  • Evidence: Alcohol abstinence lowers AF recurrence, and smoking cessation is linked to lower incident AF risk.15,16

 

References

  1. Mills MT, Futyma P, Calvert P, et al. Lifestyle and risk factor modification in atrial fibrillation: a European Heart Rhythm Association survey. Europace. 2025;27(4):euaf075. doi:10.1093/europace/euaf075
  2. Osmancik P, Roubicek T, Havranek S, et al. Catheter ablation vs lifestyle modification with antiarrhythmic drugs to treat atrial fibrillation: PRAGUE-25 Trial. J Am Coll Cardiol. 2025;86(1):18-28. doi:10.1016/j.jacc.2025.04.042
  3. Martínez-Ibáñez P, Marco-Moreno I, García-Sempere A, et al, for the ADAMPA Research Group. Long-Term Effect of Home Blood Pressure Self-Monitoring Plus Medication Self-Titration for Patients With Hypertension: A Secondary Analysis of the ADAMPA Randomized Clinical Trial. JAMA Netw Open. 2024;7(5):e2410063. doi:10.1001/jamanetworkopen.2024.10063
  4. The Science Behind the DASH Eating Plan. National Heart, Lung, and Blood Institute. Published December 29, 2021. Accessed January 17, 2026. https://www.nhlbi.nih.gov/education/dash/research?utm_source=chatgpt.com
  5. Hartnett J, Chouman N, Donnellan E. Risk-factor modification to prevent recurrent atrial fibrillation after catheter ablation. Cleve Clin J Med. 2025;92(1):53-61. doi:10.3949/ccjm.92a.24011
  6. Tanaka N, Okada M, Tanaka K, et al. Impact of long-term CPAP adherence on recurrence after atrial fibrillation ablation in patients with severe sleep apnea. J Am Heart Assoc. 2025;14(10):e038742. doi:10.1161/JAHA.124.038742
  7. Pivetta B, Chen L, Nagappa M, et al. Use and performance of the STOP-Bang questionnaire for obstructive sleep apnea screening across geographic regions: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e211009. doi:10.1001/jamanetworkopen.2021.1009
  8. Rathi KK, Saleem U, Wahaj Z, et al. Effects of continuous positive airway pressure therapy on the recurrence and progression of atrial fibrillation in patients with concomitant obstructive sleep apnea: a systematic review. Sleep Sci Pract. 2025;9:21. doi:10.1186/s41606-025-00140-z
  9. Buckley B Jr, Long L, Lane DA, et al. Exercise based cardiac rehabilitation for atrial fibrillation: Cochrane systematic review, meta-analysis, meta-regression and trial sequential analysis. Br J Sports Med. 2025;59(17):1242-1253. doi:10.1136/bjsports-2024-109149
  10. Kumbhani DJ. An exercise and physical activity program in patients with atrial fibrillation - ACTIVE-AF. American College of Cardiology. Published April 23, 2023. Accessed January 17, 2026. https://www.acc.org/latest-in-cardiology/clinical-trials/2023/04/26/14/24/active-af?utm_source=chatgpt.com
  11. Garnvik LE, Malmo V, Janszky I, et al. Eur Heart J. 2020;41(15):1467-1475. doi:10.1093/eurheartj/ehaa032
  12. Yao, H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024:384:e076410. doi:10.1136/bmj-2023-076410
  13. Gupta P, Pozzilli P. Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists. Diabetes Res Clin Pract. 2025:228:112434. doi:10.1016/j.diabres.2025.112434
  14. Karakasis P, Vlachos K, Antoniadis AP, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2026;175:156463. doi:10.1016/j.metabol.2025.15646
  15. Voskoboinik A, Kalman JM, De Silva A, et al. Alcohol abstinence in drinkers with atrial fibrillation. N Engl J Med. 2020;382(1):20-28. doi:10.1056/NEJMoa1817591
  16. Teraoka JT, Tang JJ, Delling FN, Vittinghoff E, Marcus GM. Smoking cessation and incident atrial fibrillation in a longitudinal cohort. JACC Clin Electrophysiol. 2024;10(10):2198-2206. doi:10.1016/j.jacep.2024.06.019

 

Back to top